Skip to main content

Table 3 Patients treatment and outcomes

From: Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China

Patient noStageSurgeryFurther therapyResponseTime to relapse (months)Site of relapseOverall survival (months)
1IUniCHOP+RT + ITCR38.77skin, CNS40.77
2IIBilR-CHOP+CHOPCR  116.47+
3IVUniNoPD  6.07
4IBilunknownunknownunknownunknown112.1+
5unknownUniunknownunknownunknownunknown89.97+
6IIUniR-CHOP+CHOPPR  3.4+
7IIUniR-CHOPCR  79.27
8IUniR-CHOP+RT + ITCR71.2maxillary sinus78.37+
9IUniunknownunknownunknownunknown77.53+
10IUniR-CHOP+ITCR54.23CNS76.63+
11IIIUniR-CHOP+ITCR  71.8+
12IUniR-CHOP+RT + ITCR  69.53+
13IIIUniR-CHOP+RT + ITSD  28
14IUniNoCR  44.63+
15IVUniR-CHOP+ITPD  3.1
16IUniNoCR  34.93+
17IUniunknownunknownunknownunknown34.17+
18IIUniR-CHOP+RT + ITCR  33.47+
19IUniNoCR12.77right neck21.97
20IUniNoCR8.6soft tissue16.2
21IUniRTCR2.6right testis53.63+
22unknownBiopsyunknownunknownunknownunknown28.9+
23IUniR-CHOPCR  11.8+
24IUniR-CHOPCR  4.63+
25IIUniunknownunknownunknownunknown93.23+
26IVBilNoPD  22.57
27IIIBilNoPD  35.27
28IVBiopsyNoPD  12.17
  1. Table 3 note: Uni Unilateral; Bil, Bilateral, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (rituximab Cyclophosphamide, doxorubicin, vincristine, prednisone), RT Radiotherapy, IT Intrathecal, CR Complete remission, SD Stable disease, PD Progressive disease, PR Partial remission, CNS Central nervous system.